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Suzanne D. Turner
Abstract
Anaplastic large cell lymphoma (ALCL) describes a distinct group of T cell 
lymphomas characterised by cell surface expression of CD30. At least three entities 
of ALCL exist, with similar cellular morphology but varying clinical courses and 
pathology: systemic ALCL, anaplastic lymphoma kinase (ALK)-positive, systemic 
ALCL ALK− and primary cutaneous ALCL. A fourth provisional entity associated 
with breast implants has been proposed, named breast implant-associated (BIA)-
ALCL. ALCL have varying clinical outcomes, affect both children and adults, and 
range from being well-characterised at the genetic level to relatively unknown, 
predominantly due to the relative rarity of this group of malignancies. Current 
therapeutic approaches include standard chemotherapeutic agents as well as novel 
drugs including monoclonal antibodies and kinase inhibitors.
Keywords: anaplastic large cell lymphoma, anaplastic lymphoma kinase,  
tyrosine kinase inhibitors, peripheral T cell lymphoma, BIA-ALCL
1. Introduction
Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a CD30-
positive (or ki-1+) histiocytic lymphoma, later re-classified as a distinct clinical 
entity, ALCL [1]. The presence of a chromosomal translocation in this malignancy 
was described independently by several authors in 1989–1990 [2–5]. This was 
further refined in 1994 on cloning of the t(2;5)(p23;q35) translocation breakpoint 
product, identified as a fusion protein of Nucleophosmin 1 (NPM) and anaplastic 
lymphoma kinase (ALK), the latter a previously uncharacterized protein named 
after the disease from which it was cloned [6]. Sometime later in 2008, systemic 
(s) ALCL was divided into two provisional entities: ALCL, ALK+ and ALCL, 
ALK− which were confirmed as distinct entities in the revised 4th edition of the 
WHO classification of tumours of haemopoietic and lymphoid tissues [7]. The 
revised 4th edition also includes a new provisional entity of ALCL associated with 
breast implants, breast implant-associated (BIA)-ALCL which may consist of at 
least two clinically distinguishable forms, if not a spectrum of disease, ranging 
from sub-capsular seroma fluid to aggressive, infiltrating masses with good and 
poor prognoses respectively [8, 9]. As well as systemic forms of the disease, there 
exists a cutaneous type belonging to the class of primary cutaneous CD30-positive 
T cell lymphoproliferative disorders—primary cutaneous (pc) ALCL [7]. In 
this chapter, the clinical and pathological presentations of each of these disease 
entities will be presented and discussed as will the biology underlying these 
malignancies.
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2. Systemic ALCL
2.1 Clinical course
The large majority of ALCL, ALK+ are diagnosed in a younger patient  population 
with a median age of 10.2–11 and have a relatively good prognosis (>80% overall 
survival; OS) [10–15]. In contrast ALCL, ALK− more often affects an older demo-
graphic (40–65 years of age) and has a poor prognosis (<50% OS) [16–19]. Whether 
these different clinical outcomes are age-related or due to inherent properties of the 
malignancies remains to be determined although in support of the latter, ALK− ALCL 
carrying DUSP22 rearrangements have been reported to have a superior 5-year OS 
of 90% (compared to 17% for TP63 rearranged cases and 42% for ALK−/DUSP22−/
TP63− cases) although if patients are stratified according to age rather than ALK 
status, the outcome in response to treatment is the same [17, 19, 20]. The relatively 
high survival rates of patients diagnosed with ALCL, ALK+ may also be attributable 
to the host immune response whereby cytotoxic T lymphocytes, helper T cells and B 
cells responding to ALK have been detected in patients [21, 22]. Patients with ALCL, 
ALK+ mount an immune response to the ALK protein in the form of a humoral 
antibody response [23]. In fact, the titre of ALK autoantibodies in a patient’s serum 
can be predictive of outcome with an inverse correlation between ALK antibodies and 
relapse [24]. This prognostic factor can be extended further when combined with the 
presence or absence of minimal disseminated disease (MDD), with children having 
low ALK autoantibody titres combined with presence of MDD being of high risk, 
with the converse indicative of low risk [25].
2.2 Histopathological presentation and immunophenotype
ALCL spans a broad morphological spectrum with sub-types including common 
(65%), small cell and lymphohistiocytic variants (32% combined) with the latter 
constituting a poor prognostic variable [26–28]. The unifying feature of ALCL is 
the presence of CD30 expression on the surface of the tumour cells, particularly the 
larger ones. CD30 is a marker of activated immune cells but does not distinguish 
between a T or B cell origin when applied in isolation. Hence, for a diagnosis of a T cell 
lymphoma, a cell surface protein, or combination of proteins unique to T cells must 
be detected. In this regard, many ALCL express CD4, CD2 and/or CD5 but often lack 
CD3. The positive expression of CD4 in the absence of CD8 combined with the pres-
ence of cytotoxic proteins such as TIA-1, Granzyme B and/or perforin is at odds with 
the presumed cytotoxic T cell origin of ALCL [7, 29]. However, in some cases, no T cell 
specific proteins are detectable and these are categorised as being ‘null cell’, although 
the majority demonstrate molecular rearrangements of the T cell receptor (TCR) [30].
2.3 Underlying genetic alterations
2.3.1 ALCL, ALK+
ALCL is, in general, a genetically stable cancer with few common defining genetic 
alterations besides translocations involving ALK [31, 32]. In this regard, the t(2;5)
(p23;q35) generating NPM-ALK at the breakpoint is the most common event with 
many variants having been published over the years (Table 1) [33]. The common 
expression of NPM-ALK, and its nuclear and cytoplasmic location as opposed to 
cytoplasmic-alone position as seen with many of the other variants, may account for 
its predominance in ALCL, ALK+; nuclear location may provide a competitive advan-
tage over cytoplasmic alone. Alternatively, the NPM1 gene on chromosome 5 may be 
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more prone to breakage and fusion with new partners due to its active transcription at 
the same time as ALK, although there is no evidence to suggest this is the case. What 
is clear, is that all reported ALK fusion proteins generate a hyperactive tyrosine kinase 
that is ligand-independent, driving cellular proliferation and survival [33]. Taking 
the example of NPM-ALK, this fusion protein retains the oligomerisation domains 
of NPM1 and the entire intracellular portion of ALK encoding the kinase domain, 
resulting in dimerization, auto-phosphorylation and subsequent hyperactivity initiat-
ing a whole plethora of signal transduction pathways (Figure 1) [6, 34].
Chromosomal 
alteration
Fusion protein Cellular location References
t(2;5)(p23;q35) NPM-ALK Nucleus and cytoplasm [2–6]
t(2;3)(p23;q12.2) TFG-ALK (short, long and 
extra-long isoforms)
Cytoplasm [134, 135]
t(1;2)(q25;p23) TPM3-ALK Cytoplasm [136]
Inv(2)(p23;q35) ATIC-ALK Cytoplasm [137, 138]
t(X;2)(q11–12;p23) MSN-ALK Membrane [139]
t(2;17)(p23;q23) CLTC-ALK Cytoplasm (granular) [140, 141]
t(2;22)(p23;q11.2) MYH9-ALK Cytoplasm [142]
t(2;19)(p23;q13.1) TPM4-ALK Cytoplasm [143]
t(2;17)(p23;q25) RNF213/ALO17-ALK Cytoplasm [144]
Table 1. 
Overview of ALK fusion partners identified in ALCL, ALK+.
Figure 1. 
NPM-ALK activates a plethora of signalling pathways conferring many of the cancer hallmarks on tumour 
cells. NPM-ALK autophosphorylates tyrosine residues providing docking sites for SH2 domain-containing 
proteins and the development of a signalosome consisting of at least 46 proteins [35]. Key pathways involved in 
cell survival and proliferation include the PI 3-Kinase/Akt, Ras/MAP Kinase and JAK/STAT pathways as well 
as PLCγ [36–41]. While activation of JNK and PI 3-Kinase by NPM-ALK can drive cell proliferation, they 
also inactivate p53 by ubiquitin-mediated degradation [42]. NPM-ALK also activates immunomodulatory 
pathways including up-regulation of PDL1 mediated by STAT3, as well as silencing some proteins by epigenetic 
means (green arrow, Figure 1), including those associated with signalling downstream of a functional TCR 
[43–47]. In addition, NPM-ALK directs metabolic activity of the cells shifting to aerobic glycolysis with 
increased lactate and biomass production promoting cell survival [48].
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While ALK translocations are diagnostic of ALCL, ALK+ and are central 
to disease pathogenesis, the role of other contributing mutations is largely 
unknown as few consistent genetic abnormalities besides those generating ALK 
translocations have been reported. This may, in part, be due to the plethora a 
cancer hallmarks that can be driven by NPM-ALK alone (Figure 1). However, 
array comparative genomic hybridization (aCGH) studies have highlighted some 
commonalities [31, 32]. For example, gains of chromosomes 7, 6q, 17p, 17q24-qter 
and losses of chromosomes 4q13-q21, 11q14 and 13q although the significance 
of these is unknown [32]. However, a higher number of genomic imbalances 
as detected by aCGH at a resolution of 1 MB, has been associated with a worse 
prognosis [31].
The recognition of NPM-ALK as a driving oncogenic event and the paucity of 
other reported consistent genomic/genetic abnormalities in ALCL, ALK+ has led 
to studies of the epigenetics of ALCL [31, 49, 50]. Profiling of CpG methylation in 
ALCL defined a number of genes silenced in these malignancies including the TCR 
signalling-related proteins Zap70, LAT, CD3ε, SLP76 and the IL2Rγ chain  
[43, 45–47, 49, 51]. Given that NPM-ALK can substitute for signalling normally 
induced via an engaged TCR, activation of these proximal TCR signalling proteins 
may be detrimental to cell survival resulting in their evolutionary down-regulation 
[38, 52]. Furthermore, a number of miRNA have been implicated in tumorigenesis 
including miR17-92, miR135b, miR29a and miR16 [53–56].
2.3.2 ALCL, ALK−
By their very definition, ALCL, ALK− lack expression of ALK fusion proteins, 
but until recently, few studies had found major contributory and consistent muta-
tions. DUSP22 rearrangements leading to loss of expression of DUSP22 have been 
reported in as many as 30% of cases and activating JAK1/STAT3 mutations in 20% 
[19, 57, 58]. In addition, rearrangements leading to TP63 mutation (8% of cases) 
and ERBB4 truncation have been demonstrated as have novel, rare rearrangements 
leading to the generation of NcoR2-ROS1, NFkB2-ROS1 and NFkB2-TYK2 fusion 
proteins [19, 57, 59, 60]. In addition, similar to ALK+ ALCL, miRNA have been 
implicated in disease pathogenesis including miR155 as well as others that enable 
a molecular distinction between ALCL, ALK+ and ALK− as well as peripheral T 
cell lymphoma, not otherwise specified (PTCL-NOS) [61–64]. Likewise, genomic 
classifiers of ALCL, ALK− amongst other peripheral T cell lymphomas have been 
demonstrated using a variety of genomic analysis techniques and includes the dif-
ferentiating 3-gene signature of TNFRSF8, BATF3 and TMOD1 [65–68]. SNP arrays 
have also led to the identification of recurrent losses at 17p13 and/or 6q21 where the 
TP53 and PRDM1 genes are located respectively, in as many as 52% of cases sugges-
tive of a role for the loss of the p53 and BLIMP1 proteins in disease pathogenesis [69].
3. BIA-ALCL
BIA-ALCL is a relatively new addition to the spectrum of ALCL, although the 
first case was reported in 1997, but did not receive much attention until further cases 
were identified and published, and the FDA acknowledged an association in 2011 [70, 
71]. In March 2015, the French health minister issued a warning following reports 
of 18 cases in France [72]. A further follow-up report released by the FDA in 2017 
described 414 medical device reports and 9 deaths associated with BIA-ALCL [73]. 
Many case series have been reviewed and reported since, with data from France, Italy, 
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The Netherlands, UK, Australia and the USA being prevalent [74–80]. Most recently, 
seven cases have been reported in Latin America [81]. There are approximately 5–10 
million women with breast implants worldwide with rates of BIA-ALCL being pro-
portionately rare although difficult to put an exact figure to. Dependent on the study 
conducted, incidence rates range from 1 to 89 cases per million women with breast 
implants [82, 83]. This reaches a much higher incidence if one considers women with 
textured implants alone. Almost all cases reported to date have been associated with 
a breast implant of a textured surface at some point during the history of the patient; 
whilst rare cases have been reported in women with smooth implants, the patient had 
been in receipt of a textured implant at some stage [78, 84]. In addition, both saline 
and silicone filled implants have been implicated in patients with BIA-ALCL. The 
tumour cells generally present as a monoclonal expansion of CD30-positive cells, as 
an effusion within the fibrous capsule surrounding the implant [78].
3.1 Clinical course
BIA-ALCL appears to represent at least two clinical entities if not a spectrum 
of malignancies; patients present on most occasions with an indolent seroma with 
rarer incidences of invasive solid masses [77]. Indeed, cases have been reported of 
tumour growth into the ribs with metastases to distant lymph nodes [85, 86].
3.2 Histopathological presentation and immunophenotype
Like sALCL, BIA-ALCL is characterised by CD30 expression on lymphoid cells, 
in the latter situation contained within the peri-prosthetic effusion [28, 87]. These 
cells can be detected by immunohistochemistry, cytology and flow cytometry of 
seroma fluid or any solid mass [85]. A Th17/Th1 origin has been proposed whereby 
tumour cells secrete IFNγ, IL6, IL8, IL17 and TGFβ although a Th2 derivation has 
also been put forward [88–90].
3.3 Underlying genetic alterations
Like ALCL, ALK−, BIA-ALCL has not to date been associated with genomic 
events leading to activation of ALK. However, in concert with ALCL, ALK−, 
activating mutations of JAK/STAT proteins have been reported in a very few cases 
[91, 92]. Given the relative rarity of this disease, larger scale studies are required to 
elucidate the underlying genetics.
4. Primary cutaneous ALCL
While skin involvement can occur as an extranodal manifestation of sALCL, 
isolated cutaneous disease can also occur, although this is largely ALK-negative [17]. 
Primary cutaneous ALCL belongs to the spectrum of CD30 positive lymphopro-
liferative disorders (LPDs) and like BIA-ALCL is largely indolent in nature. While 
largely affecting adults who present with isolated, ulcerating nodules, children can 
also develop pcALCL.
4.1 Clinical course
Like systemic ALCL, ALK−, cutaneous ALCL is also a disease of an older 
demographic with the majority of patients being over 50 years of age, yet is closer 
Peripheral T-cell Lymphomas
6
to ALCL, ALK+ in its prognosis, reaching a 5-year OS of over 90% [17]. However, 
relapse is relatively common in this patient group occurring in as many as 30–40% 
of patients and some rare cases (12–16%) can progress to systemic disease [93–95]. 
Spontaneous regression has been reported, although in rare cases with partial 
regressions being more common [96].
4.2 Histopathological presentation and immunophenotype
Diagnosis can be difficult with other cutaneous T cell lymphomas such as 
lymphomatoid papulosis (LyP) and transformed mycosis fungoides (MF) pro-
viding differential diagnoses [9]. However, like systemic ALCL, CD30 expression 
is a defining feature of this malignancy as it is for the other CD30-associated 
LPDs.
4.3 Underlying genetic alterations
Due to its relative rarity, sometimes-difficult diagnosis and indolent course, 
studies of the underlying genetics are few. However, limited studies have elucidated 
some of the genetic events that may be driving this disease process some of which 
are also common to sALCL. For example, as in sALCL, DUSP22-IRF4 rearrange-
ments have been detected in 20–57% of pcALCL and ALK expression is seen in 
rare cases [19, 97–101]. In addition, aCGH has identified gains of 7q31 and losses of 
6q16-21 as well as 13q34, collectively in 45% of examined patient specimens [102]. 
As well as similarities to ALCL, ALK-negative with regards to DUSP22 transloca-
tions, upregulation of miR155 has also been observed in both pcALCL and sALCL, 
ALK− [61, 103]. The functional and clinical significance of these genetic events is 
still subject to investigation.
5. Treatment of ALCL
As for most peripheral T cell lymphomas, standard combination chemotherapy 
has been the mainstay of treatment for many years, specifically in the case of 
systemic disease [14]. In contrast, the relatively indolent cutaneous and breast 
implant-associated forms are primarily treated by surgical removal [86]. However, 
as this spectrum of diseases crosses age boundaries, there are age-specific differ-
ences in therapeutic approaches.
5.1 Treatment of children with ALCL
As mentioned before, the large majority of patients diagnosed with ALCL, 
ALK+ are children and young adults. As such, the therapeutic approach is tuned 
to this patient population with children receiving a combination of chemothera-
peutic agents with survival rates in excess of 90% [10, 13, 14]. The ALCL99 trial, 
the  largest trial ever to be conducted for children diagnosed with ALCL (n = 352) 
applied a therapeutic regimen consisting of a B cell protocol (based on NHL-
BFM-B) with randomisation of vinblastine [13]. The success of this trial has led to 
most centres adopting the ALCL99 treatment protocol. Additionally, the success of 
the ALCL99 trial and the plethora of biological data produced suggest that patients 
might be stratified according to ALK autoantibody titre and the presence of MDD 
as discussed above. Indeed, vinblastine monotherapy might be more appropriate for 
low risk patients reducing both acute and chronic side-effects of the combination 
chemotherapy protocol [104, 105].
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5.2 Treatment of adults with ALCL
Adults with ALCL tend to be ALK− and are treated with the standard T 
cell lymphoma regimen CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisone) although CHOEP (CHOP + etoposide) has been demonstrated to 
be superior in the treatment of adult ALCL, ALK+ patients [106]. In the case of 
BIA-ALCL, surgical excision with complete capsulectomy is recommended and is 
often sufficient to induce remission particularly for patients that present with a 
contained seroma [85, 86]. However, patients with aggressive BIA-ALCL that has 
metastasised require radiotherapy if not chemotherapy, and anecdotal evidence 
suggests that upfront use of brentuximab vedotin (BV) may benefit these 
patients [107]. In the case of pcALCL, localised excision and/or radiotherapy 
is largely prescribed due to the obvious skin presentation, although cases with 
multi-focal lesions may require more aggressive treatment involving chemo-
therapy [108, 109].
5.3 New and novel treatment options for ALCL
In the post-genomic era, targeted agents have become the mainstay of chemo-
therapy, largely in addition to standard cytotoxic drugs. In the case of ALCL, ALK+, 
inhibitors of ALK are the obvious choice and many have been developed since the 
discovery of ALK expression in Non-Small Cell Lung Cancer [14]. The first ALK 
inhibitor to be developed was Pfizer’s PF-2341066, now known as crizotinib, a 
dual ALK/cMet inhibitor with efficacy in experimental models of ALCL, ALK+ 
[110]. However, these drugs have been slow to make their way into the clinic for the 
treatment of ALCL, largely due to its relative rarity and paediatric presentation. A 
phase I study of crizotinib for children with relapsed/refractory ALK+ malignancies 
including ALCL, reported seven out of nine patients to achieve a complete response 
(CR) [111]. A phase II expansion cohort showed overall response rates of 83 and 
90% respectively for those children receiving crizotinib at dosages of 165 and 
280 mg/m2 respectively [112]. However, discontinuation of therapy has led to rapid 
relapse of both children and adults with ALCL, ALK+ questioning the required 
window of therapy [113].
Naturally, ALK inhibitors only apply to the therapy of ALCL, ALK+. In con-
trast, the common expression of CD30 on all ALCL sub-types means that targeted 
agents to this cell surface protein should be broadly applicable [114]. In this vein, 
BV, an anti-CD30 antibody tethered to the microtubule inhibitor monomethyl 
auristatin E, has shown promising results in clinical trials, although relapse is 
again an issue with down-regulation of CD30 expression seen [115–117]. However, 
results of the Phase 3 ALCANZA trial for pcALCL and MF showed impressive 
results with an objective response rate of 67% in the BV arm (versus 20% in the 
standard treatment arm: methotrexate or bexarotene) [118]. However, BV is not 
without its side-effects with peripheral neuropathy being prominent (affect-
ing 67% of patients in the afore-mentioned trial) [118]. Likewise, results of a 
Phase 2 trial of relapsed/refractory sALCL showed peripheral neuropathy to be 
a considerable side-effect in 91% of patients although a 5-year OS of 79% was 
achieved (69% CR, 80% ORR for ALK+ patients and 52% CR, 81% ORR for ALK−) 
[119]. A randomised Phase 3 trial to establish the efficacy of BV in combination 
with cyclophosphamide, doxorubicin and prednisolone, in comparison to these 
chemotherapeutic agents given with vincristine in place of BV, is ongoing for the 
frontline treatment of CD30-positive lymphomas including ALCL (ECHELON 
2; NCT01777152). Other potential therapeutic targets for the treatment of ALCL 
include PDGFR, JAK/STAT, PD-1/PDL1 and reactivation of p53 [42, 44, 120, 121].  
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Indeed, biological studies have identified a number of potential therapeutic 
targets, which in some cases, and with time, have been matched to available drugs. 
However, with relatively few patients, coupled with a good prognosis, at least for 
children with ALK+ systemic disease, it is difficult to formulate trials to test these 
agents.
A further approach given the immune response to ALK in patients with ALK-
positive disease, is a vaccination strategy [122]. This is especially relevant as ALK 
expression seems to be limited to tissues of neonatal origin suggesting that side-
effects will be limited [123].
6.  The origins and pathogenesis of ALCL: a common origin with 
distinct pathogenesis or different origins converging on a shared 
histopathology?
6.1 Cell of origin
Systemic ALCL presents in the periphery suggestive of a peripheral T cell 
origin, although as many as 50% of children show mediastinal involvement [29]. 
In this latter vein, a thymic origin has been proposed whereby gene expression 
signatures associated with early thymic progenitors (ETP) are detected in ALCL 
cancer stem cells, in fitting with the detection of transcripts for the t(2;5)(p23;q35) 
translocation breakpoint product in 2% of cord blood specimens from healthy 
babies [124, 125]. In addition, studies of epigenetic signatures are in keeping with 
an ETP origin [49]. As such, it is not inconceivable that ALCL, ALK+ has a thymic, 
perhaps in utero origin in-line with the pathogenesis of paediatric leukaemias [29]. 
Additionally, this is in keeping with a paediatric presentation and the early-life 
involution of the thymus. Furthermore, studies of murine models show that events 
in the periphery once incipient tumour cells emerge from the thymus contribute to 
disease pathogenesis as discussed below [30].
While ALCL, ALK+ is proposed to emerge from the thymus, a similar origin 
likely does not apply to ALK-negative disease, including pcALCL, BIA-ALCL and 
ALCL, ALK−. In these latter cases, circulating peripheral T cells are most prob-
ably the cells of origin given the older age of diagnosis and peripheral location, 
particularly with regards to BIA-ALCL and pcALCL. If this is the case, if the type of 
T cell that becomes transformed can be identified, this may give clues as to disease 
pathogenesis. While histopathology indicating an activated CD30-expressing T cell 
producing cytotoxic proteins, yet also often retaining CD4 expression, has given 
rise to a presumed cytotoxic T cell origin, recent data challenges this perception [29, 
126]. Specifically, analysis of gene expression data suggests a Th17 origin, a T cell 
that usually responds to large extracellular infectious agents such as bacteria and is 
often implicated in autoimmune disease [89, 127]. However, given that ALCL often 
lack expression of TCR-related signalling proteins as well as a functional cell surface 
TCR, analogies to innate lymphoid cells (ILC), specifically ILC type 3 cells are also 
apparent [127]. Naturally, the eventual cell phenotype is not necessarily reflec-
tive of the cell of origin with environmental events likely contributing to the final 
observed identity. In this regard, whether in ALCL, ALK+ this is shaped by ALK-
mediated activities (or is the consequence of other induced (epi)genetic events) 
remains to be fully elucidated as it does for other ALCL sub-types. In evidence, it 
has been shown that NPM-ALK induces expression of cytotoxic proteins suggesting 
that their presence reflects the activities of this inherent transforming event rather 
than a property of the cell of origin, at least for ALCL, ALK+ [128]. This would 
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partly explain the ‘confused’ T cell phenotype with both helper and cytotoxic T cell 
properties apparent. Indeed, plasticity amongst helper T cell subsets is immense 
and is dependent on the relative expression levels of key transcription factors such 
as T-bet, RORγ, GATA-3 and Foxp3 as well as cytokines in the microenvironment 
[129]. Hence, for a T cell aberrantly expressing a variety of genetic changes, embed-
ded in specific inflammatory microenvironments, the resultant cell surface pheno-
type may no longer reflect the cell of origin.
Another factor to consider is genetic predisposition or health status of the 
patients whereby some, with for example, autoimmune disease or allergies and a 
preponderance of Th17 or Th1/Th2 cells respectively may be more at risk, with the 
resultant tumour phenotype dependent on this. In evidence, at least for BIA-ALCL 
Th1, Th2 and Th17 origins have been proposed based on the profile of secreted 
cytokines and expression of specific transcription factors, although of course none 
of these factors in isolation are necessarily truly indicative of the cell of origin, 
and as mentioned before, the contribution of the microenvironment cannot be 
discounted [88–90].
6.2 An infectious aetiology?
The common expression of CD30 on all entities of ALCL is suggestive of an 
infectious aetiology whereby activation of the underlying T cells triggers expres-
sion of this cell surface protein. However, individual cell surface proteins in isola-
tion are not necessarily indicative of the cell of origin of any given cancer, which 
combined with the propensity of cancer cells to aberrantly up- or down-regulate 
expression of proteins according to evolutionary fitness necessitates further 
evidence to draw conclusive decisions. Yet, in evidence of an infectious aetiology, 
Figure 2. 
Proposed mechanisms of tumorigenesis for ALCL. Data suggest that the NPM-ALK generating chromosomal 
translocation occurs in primitive haemopoietic cells, such as early thymic progenitors, whereby aberrant TCR 
rearrangements are tolerated [30]. Incipient tumour cells then exit into the periphery where secondary events 
lead to transformation. Conversely, systemic ALCL, ALK−, pcALCL and BIA-ALCL more likely initiate 
in circulating peripheral T cells whereby chronic antigenic stimulation mediated by infectious agents, an 
inflammatory milieu and/or toxic insult leads to the acquisition of malignancy-promoting mutations and 
cellular transformation.
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sALCL have been reported in the context of insect and tick bites, as well as bacte-
rial infections on the surface of breast implants in BIA-ALCL and in association 
with cutaneous T cell lymphomas whereby TLRs 2, 4 and 7 are expressed by 
tumour cells [130–132]. Such infectious aetiologies would also produce an inflam-
matory microenvironment dictated by the infectious agent whereby cytokines, 
growth factors and many cell types involved in inflammation would be present 
and may contribute to disease pathogenesis. In this regard, the lymphohistiocytic 
subtype of sALCL is, as its name suggests, infiltrated with macrophages and many 
cytokines have been detected at elevated levels in patients diagnosed with ALCL, 
ALK+ [26, 133] (Figure 2).
7. Conclusions
ALCL is a diverse disease entity affecting a range of patients ranging from 
children to women with breast implants. What is clear, is that all ALCL share 
some common immunohistopathological features, most prominently CD30 
expression, but the clinical courses of these diseases vary considerably from 
the indolent LPD, pcALCL through to aggressive, poor prognostic malignan-
cies such as sALCL, ALK−. Our understanding of the underlying biology is 
improving year on year and has had a significant impact on clinical decision 
making including therapeutic approaches. While for many forms of ALCL, 
therapy has not altered considerably over the past decade, novel targeted 
approaches to treatment are entering the clinical arena ranging from mono-
clonal antibodies to kinase inhibitors. Indeed, we are now in the fortunate 
position whereby there are a plethora of therapeutic agents, but too few 
patients to trial them.
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